Ardelyx, Inc. (ARDX): Price and Financial Metrics

Ardelyx, Inc. (ARDX): $9.32

0.14 (-1.48%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add ARDX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#292 of 360

in industry

ARDX Price/Volume Stats

Current price $9.32 52-week high $10.13
Prev. close $9.46 52-week low $2.82
Day low $9.21 Volume 4,570,300
Day high $9.72 Avg. volume 6,646,292
50-day MA $8.26 Dividend yield N/A
200-day MA $5.03 Market Cap 2.17B

ARDX Stock Price Chart Interactive Chart >

ARDX POWR Grades

  • ARDX scores best on the Sentiment dimension, with a Sentiment rank ahead of 65.13% of US stocks.
  • ARDX's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • ARDX ranks lowest in Stability; there it ranks in the 0th percentile.

ARDX Stock Summary

  • ARDX's price/sales ratio is 10.63; that's higher than the P/S ratio of 90.03% of US stocks.
  • Over the past twelve months, ARDX has reported earnings growth of -79.99%, putting it ahead of merely 16.86% of US stocks in our set.
  • Revenue growth over the past 12 months for ARDELYX INC comes in at 1,390.41%, a number that bests 99.45% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ARDELYX INC are AXSM, BFRG, ITCI, PRCT, and SEED.
  • Visit ARDX's SEC page to see the company's official filings. To visit the company's web site, go to www.ardelyx.com.

ARDX Valuation Summary

  • ARDX's price/earnings ratio is -54.2; this is 285.93% lower than that of the median Healthcare stock.
  • Over the past 116 months, ARDX's price/sales ratio has gone up 2.3.

Below are key valuation metrics over time for ARDX.

Stock Date P/S P/B P/E EV/EBIT
ARDX 2023-12-29 10.7 7.5 -54.2 -65.0
ARDX 2023-12-28 11.1 7.8 -56.1 -67.3
ARDX 2023-12-27 11.3 7.9 -57.0 -68.3
ARDX 2023-12-26 11.2 7.9 -56.5 -67.8
ARDX 2023-12-22 11.0 7.7 -55.5 -66.6
ARDX 2023-12-21 10.9 7.6 -55.0 -65.9

ARDX Growth Metrics

    The 5 year price growth rate now stands at -43%.
  • The year over year price growth rate now stands at -87.34%.
  • The 4 year net cashflow from operations growth rate now stands at 17.98%.
ARDX's revenue has moved up $3,728,000 over the prior 33 months.

The table below shows ARDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 9.009 -123.797 -114.136
2022-06-30 5.196 -132.959 -134.83
2022-03-31 3.983 -135.954 -153.081
2021-12-31 10.097 -152.551 -158.165
2021-09-30 10.877 -130.672 -150.807
2021-06-30 12.417 -115.96 -125.328

ARDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARDX has a Quality Grade of C, ranking ahead of 26.73% of graded US stocks.
  • ARDX's asset turnover comes in at 0.061 -- ranking 306th of 682 Pharmaceutical Products stocks.
  • XBIO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with ARDX.

The table below shows ARDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 0.919 -0.887
2021-03-31 0.063 0.912 -0.724
2020-12-31 0.036 0.981 -0.618
2020-09-30 0.035 0.982 -0.579
2020-06-30 0.040 0.911 -0.719
2020-03-31 0.035 0.908 -0.806

ARDX Price Target

For more insight on analysts targets of ARDX, see our ARDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.21 Average Broker Recommendation 1.62 (Moderate Buy)

Ardelyx, Inc. (ARDX) Company Bio


Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The company was founded in 2007 and is based in Fremont, California.


ARDX Latest News Stream


Event/Time News Detail
Loading, please wait...

ARDX Latest Social Stream


Loading social stream, please wait...

View Full ARDX Social Stream

Latest ARDX News From Around the Web

Below are the latest news stories about ARDELYX INC that investors may wish to consider to help them evaluate ARDX as an investment opportunity.

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on December 18, 2023, the compensation committee of the company’s board of directors granted sixteen new non-executive employees options to purchase an aggregate of 257,119 shares of the company’s common stock, and granted eighte

Yahoo | December 20, 2023

There's Reason For Concern Over Ardelyx, Inc.'s (NASDAQ:ARDX) Massive 36% Price Jump

Despite an already strong run, Ardelyx, Inc. ( NASDAQ:ARDX ) shares have been powering on, with a gain of 36% in the...

Yahoo | December 18, 2023

3 Short-Squeeze Stocks Ready for a Year-End Rally

These are a few companies that have seen considerable gains this year that still have a large percentage of short interest.

Noah Bolton on InvestorPlace | December 14, 2023

3 Stocks at the Forefront of Personalized Medicine Trend

In the rapidly evolving healthcare sector, the idea of personalized medicine stocks stands out, revolutionizing patient care by tailoring treatments with their individual genetic profiles. These stocks highlight the trend of focusing on genetic and molecular characteristics, promising more effective healthcare solutions. This trend transcends medical innovation, marking its territory as a burgeoning economic powerhouse. Grand View Research forecasts the global personalized medicine market to rea

Yahoo | December 5, 2023

7 Penny Stocks You’ll Regret Not Buying Soon: November 2023

Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time.

Muslim Farooque on InvestorPlace | November 21, 2023

Read More 'ARDX' Stories Here

ARDX Price Returns

1-mo 6.76%
3-mo 95.80%
6-mo 93.36%
1-year 222.49%
3-year 37.67%
5-year 207.59%
YTD 50.32%
2023 117.54%
2022 159.09%
2021 -83.00%
2020 -13.79%
2019 319.27%

Continue Researching ARDX

Here are a few links from around the web to help you further your research on Ardelyx Inc's stock as an investment opportunity:

Ardelyx Inc (ARDX) Stock Price | Nasdaq
Ardelyx Inc (ARDX) Stock Quote, History and News - Yahoo Finance
Ardelyx Inc (ARDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!